Published in Heart on November 01, 2004
Homocysteine is associated with the progression of non-culprit coronary lesions in elderly acute coronary syndrome patients after percutaneous coronary intervention. J Geriatr Cardiol (2016) 0.90
Hyperhomocysteinemia accelerates collagen accumulation in the adventitia of balloon-injured rat carotid arteries via angiotensin II type 1 receptor. Int J Mol Sci (2014) 0.75
Homocysteine and risk of ischemic heart disease and stroke: a meta-analysis. JAMA (2002) 8.11
Thrombolysis in Myocardial Infarction (TIMI) Trial, Phase I: A comparison between intravenous tissue plasminogen activator and intravenous streptokinase. Clinical findings through hospital discharge. Circulation (1987) 5.73
Long-term follow-up of patients with mild coronary artery disease and endothelial dysfunction. Circulation (2000) 5.53
Plasma homocysteine levels and mortality in patients with coronary artery disease. N Engl J Med (1997) 5.35
Decreased rate of coronary restenosis after lowering of plasma homocysteine levels. N Engl J Med (2001) 5.09
Folic acid improves endothelial function in coronary artery disease via mechanisms largely independent of homocysteine lowering. Circulation (2002) 1.98
Rapid, fully automated measurement of plasma homocyst(e)ine with the Abbott IMx analyzer. Clin Chem (1995) 1.57
5-methyltetrahydrofolate, the active form of folic acid, restores endothelial function in familial hypercholesterolemia. Circulation (1998) 1.27
Clinical and quantitative coronary angiographic predictors of coronary restenosis: a comparative analysis from the balloon-to-stent era. J Am Coll Cardiol (2001) 1.17
Plasma homocysteine predicts mortality independently of traditional risk factors and C-reactive protein in patients with angiographically defined coronary artery disease. Circulation (2000) 1.11
Can dietary supplements with folic acid or vitamin B6 reduce cardiovascular risk? Design of clinical trials to test the homocysteine hypothesis of vascular disease. J Cardiovasc Risk (1998) 1.04
Remodeling of human coronary arteries undergoing coronary angioplasty or atherectomy. Circulation (1997) 0.96
Late regression of the dilated site after coronary angioplasty: a 5-year quantitative angiographic study. Circulation (1997) 0.87
Coronary endothelial function in hyperhomocysteinemia: improvement after treatment with folic acid and cobalamin in patients with coronary artery disease. J Am Coll Cardiol (2002) 0.87
Association of plasma homocysteine with restenosis after percutaneous coronary angioplasty. Eur Heart J (2002) 0.87
Fish and long-chain omega-3 fatty acids could be lifesavers for diabetic women. Circulation (2003) 0.78
Homocysteine, lipoprotein(a), and restenosis after percutaneous transluminal coronary angioplasty: a prospective study. Am Heart J (2000) 0.78
Homocysteine--an innocent bystander in vascular disease? Eur Heart J (2001) 0.78
Left ventricular end-systolic volume as the major determinant of survival after recovery from myocardial infarction. Circulation (1987) 7.14
Early revascularization in acute myocardial infarction complicated by cardiogenic shock. SHOCK Investigators. Should We Emergently Revascularize Occluded Coronaries for Cardiogenic Shock. N Engl J Med (1999) 6.93
Insights into the evolution of Yersinia pestis through whole-genome comparison with Yersinia pseudotuberculosis. Proc Natl Acad Sci U S A (2004) 5.09
Sex, clinical presentation, and outcome in patients with acute coronary syndromes. Global Use of Strategies to Open Occluded Coronary Arteries in Acute Coronary Syndromes IIb Investigators. N Engl J Med (1999) 4.53
Cost effectiveness of early discharge after uncomplicated acute myocardial infarction. N Engl J Med (2000) 4.19
Effect of intravenous streptokinase on left ventricular function and early survival after acute myocardial infarction. N Engl J Med (1987) 4.08
ADP dissociation from actomyosin subfragment 1 is sufficiently slow to limit the unloaded shortening velocity in vertebrate muscle. Proc Natl Acad Sci U S A (1985) 4.01
Energetics and mechanism of actomyosin adenosine triphosphatase. Biochemistry (1976) 3.97
Requirement of the chemokine receptor CXCR3 for acute allograft rejection. J Exp Med (2000) 3.84
IL-7 enhances the survival and maintains the size of naive T cells. J Immunol (2001) 3.39
Creating a pandemic of prediabetes: the proposed new diagnostic criteria for impaired fasting glycaemia. Diabetologia (2004) 3.26
Guidelines for detection and management of dyslipidaemia. Scientific Committee of the National Heart Foundation of New Zealand. N Z Med J (1993) 3.18
Difference in countries' use of resources and clinical outcome for patients with cardiogenic shock after myocardial infarction: results from the GUSTO trial. Lancet (1997) 2.80
Prospective evaluation of eligibility for thrombolytic therapy in acute myocardial infarction. BMJ (1996) 2.62
Antibiotics prevent liver injury in rats following long-term exposure to ethanol. Gastroenterology (1995) 2.58
Link between the angiographic substudy and mortality outcomes in a large randomized trial of myocardial reperfusion. Importance of early and complete infarct artery reperfusion. GUSTO-I Investigators. Circulation (1995) 2.53
Significance of smoking in patients receiving thrombolytic therapy for acute myocardial infarction. Experience gleaned from the International Tissue Plasminogen Activator/Streptokinase Mortality Trial. Circulation (1993) 2.42
Inactivation of Kupffer cells prevents early alcohol-induced liver injury. Hepatology (1994) 2.37
Donor-derived IP-10 initiates development of acute allograft rejection. J Exp Med (2001) 2.17
Plasma N-terminal pro-brain natriuretic peptide and adrenomedullin: new neurohormonal predictors of left ventricular function and prognosis after myocardial infarction. Circulation (1998) 2.17
Reperfusion after liver transplantation in rats differentially activates the mitogen-activated protein kinases. Hepatology (1997) 2.14
One-year survival following early revascularization for cardiogenic shock. JAMA (2001) 2.10
Importance of ICOS-B7RP-1 costimulation in acute and chronic allograft rejection. Nat Immunol (2001) 2.10
Stroke after thrombolysis. Mortality and functional outcomes in the GUSTO-I trial. Global Use of Strategies to Open Occluded Coronary Arteries. Circulation (1995) 2.08
Influence of diabetes mellitus on clinical outcome in the thrombolytic era of acute myocardial infarction. GUSTO-I Investigators. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries. J Am Coll Cardiol (1997) 2.08
One-year results from the Global Utilization of Streptokinase and TPA for Occluded Coronary Arteries (GUSTO-I) trial. GUSTO-I Investigators. Circulation (1996) 2.03
Special instrumentation and techniques for kinetic studies of contractile systems. Methods Enzymol (1982) 2.02
Long-term prognostic importance of patency of the infarct-related coronary artery after thrombolytic therapy for acute myocardial infarction. Circulation (1994) 2.02
[Intercultural differences in the treatment of severely injured patients with poor prognosis. Using the example of a 23-year-old Chinese patient]. Unfallchirurg (2013) 1.98
Interleukin-6 protects liver against warm ischemia/reperfusion injury and promotes hepatocyte proliferation in the rodent. Hepatology (1997) 1.95
Comparing health expenditure. N Z Med J (1996) 1.92
Effect of intravenous streptokinase as compared with that of tissue plasminogen activator on left ventricular function after first myocardial infarction. N Engl J Med (1989) 1.91
Acute myocardial infarction in the young--the role of smoking. The Investigators of the International Tissue Plasminogen Activator/Streptokinase Mortality Trial. Eur Heart J (1995) 1.90
Size and motion of the mitral valve annulus in man. I. A two-dimensional echocardiographic method and findings in normal subjects. Circulation (1981) 1.88
Age and outcome with contemporary thrombolytic therapy. Results from the GUSTO-I trial. Global Utilization of Streptokinase and TPA for Occluded coronary arteries trial. Circulation (1996) 1.87
Kinetics of the interaction between actin, ADP, and cardiac myosin-S1. J Biol Chem (1984) 1.86
Association between polycystic ovaries and extent of coronary artery disease in women having cardiac catheterization. Ann Intern Med (1997) 1.83
Platelet glycoprotein IIb/IIIa inhibitors reduce mortality in diabetic patients with non-ST-segment-elevation acute coronary syndromes. Circulation (2001) 1.83
Waiting times and prioritization for coronary artery bypass surgery in New Zealand. Heart (1999) 1.81
Temporal updating scheme for probabilistic neural network with application to satellite cloud classification--further results. IEEE Trans Neural Netw (2001) 1.80
Reduction of stroke events with pravastatin: the Prospective Pravastatin Pooling (PPP) Project. Circulation (2001) 1.78
Long-term survival and valve-related complications in young women with cardiac valve replacements. Circulation (1999) 1.77
Influence of diabetes mellitus on clinical outcomes across the spectrum of acute coronary syndromes. Findings from the GUSTO-IIb study. GUSTO IIb Investigators. Eur Heart J (2000) 1.73
The effect of reducing extracellular pH on the membrane currents of the ranvier node. Pflugers Arch (1969) 1.73
Flow cytometric analysis of leukocytes in the human female reproductive tract: comparison of fallopian tube, uterus, cervix, and vagina. Am J Reprod Immunol (1997) 1.72
Light chain 2 profile and activity of human ventricular myosin during dilated cardiomyopathy. Identification of a causal agent for impaired myocardial function. Circulation (1992) 1.70
Genetic mapping and QTL analysis of fiber-related traits in cotton ( Gossypium). Theor Appl Genet (2003) 1.66
Cardiogenic shock complicating acute myocardial infarction--etiologies, management and outcome: a report from the SHOCK Trial Registry. SHould we emergently revascularize Occluded Coronaries for cardiogenic shocK? J Am Coll Cardiol (2000) 1.66
Reinfarction after thrombolytic therapy for acute myocardial infarction followed by conservative management: incidence and effect of smoking. J Am Coll Cardiol (1990) 1.64
Characterization of brain microtubule proteins prepared by selective removal of mitochondrial and synaptosomal components. J Biol Chem (1979) 1.59
Clinical outcomes of therapeutic agents that block the platelet glycoprotein IIb/IIIa integrin in ischemic heart disease. Circulation (1999) 1.59
Effects of pravastatin in 3260 patients with unstable angina: results from the LIPID study. Lancet (2000) 1.56
Expression of CD39 by human peripheral blood CD4+ CD25+ T cells denotes a regulatory memory phenotype. Am J Transplant (2010) 1.55
Short- and long-term outcomes following atrial fibrillation in patients with acute coronary syndromes with or without ST-segment elevation. Heart (2008) 1.54
Functional connectivity MR imaging reveals cortical functional connectivity in the developing brain. AJNR Am J Neuroradiol (2008) 1.53
New Q waves on the presenting electrocardiogram independently predict increased cardiac mortality following a first ST-elevation myocardial infarction. Eur Heart J (2000) 1.51
Antimicrobial susceptibility of Haemophilus influenzae among children in Beijing, China, 1999-2000. Acta Paediatr (2002) 1.50
Platelet glycoprotein IIb/IIIa inhibition in acute coronary syndromes. Gradient of benefit related to the revascularization strategy. Eur Heart J (2002) 1.50
Randomized, double-blind comparison of hirulog versus heparin in patients receiving streptokinase and aspirin for acute myocardial infarction (HERO). Hirulog Early Reperfusion/Occlusion (HERO) Trial Investigators. Circulation (1997) 1.47
Serum troponins T and I after elective cardioversion. Eur Heart J (2000) 1.45
Increasing prevalence of gestational diabetes mellitus in Chinese women from 1999 to 2008. Diabet Med (2011) 1.43
Differential effects of cyclosporine A, methylprednisolone, mycophenolate, and rapamycin on CD154 induction and requirement for NFkappaB: implications for tolerance induction. Transplantation (2000) 1.43
Risk of intracranial haemorrhage with combined fibrinolytic and glycoprotein IIb/IIIa inhibitor therapy in acute myocardial infarction. Dichotomous response as a function of age in the GUSTO V trial. Eur Heart J (2003) 1.42
GCR1, a transcriptional activator in Saccharomyces cerevisiae, complexes with RAP1 and can function without its DNA binding domain. EMBO J (1993) 1.41
Spontaneous dissection of native coronary arteries. Heart (2005) 1.41
A cost-benefit analysis of RSV prophylaxis in high-risk infants. Ann Pharmacother (2001) 1.39
Optimal stent positioning in coronary arteries: partial balloon inflation to overcome cardiac cycle-related motion of the stent/delivery system. Catheter Cardiovasc Interv (2000) 1.39
New atrial fibrillation after acute myocardial infarction independently predicts death: the GUSTO-III experience. Am Heart J (2000) 1.39
Simvastatin therapy for hypercholesterolaemia in patients with coronary heart disease. N Z Med J (1990) 1.39
A direct threat to research in public hospitals. N Z Med J (1995) 1.39
Coronary angioplasty in New Zealand 1995-1998: a report from the National Coronary Angioplasty Registry. N Z Med J (2000) 1.38
Usefulness of the presenting electrocardiogram in predicting myocardial salvage with thrombolytic therapy in patients with a first acute myocardial infarction. Eur Heart J (2002) 1.38
Cost of coronary heart disease in New Zealand. N Z Med J (1993) 1.38
Prospective observational study of acute coronary syndromes in China: practice patterns and outcomes. Heart (2007) 1.36
Percutaneous closure of perimembranous ventricular septal defects with the eccentric Amplatzer device: multicenter follow-up study. Pediatr Cardiol (2005) 1.33
Significance of diabetes mellitus in patients with acute myocardial infarction receiving thrombolytic therapy. Investigators of the International Tissue Plasminogen Activator/Streptokinase Mortality Trial. J Am Coll Cardiol (1993) 1.33
Impact of thrombolysis, intra-aortic balloon pump counterpulsation, and their combination in cardiogenic shock complicating acute myocardial infarction: a report from the SHOCK Trial Registry. SHould we emergently revascularize Occluded Coronaries for cardiogenic shocK? J Am Coll Cardiol (2000) 1.32
Targeted deletion of CX(3)CR1 reveals a role for fractalkine in cardiac allograft rejection. J Clin Invest (2001) 1.31
Unique CD8+ T cell-rich lymphoid aggregates in human uterine endometrium. J Leukoc Biol (1997) 1.31
Tuberculosis: reasons for diagnostic delay in Auckland. N Z Med J (2000) 1.30
Chemokines and their receptors in allograft rejection. Curr Opin Immunol (2000) 1.30
Isolated CD39 expression on CD4+ T cells denotes both regulatory and memory populations. Am J Transplant (2009) 1.27
Does angiography six months after coronary intervention influence management and outcome? Benestent II Investigators. J Am Coll Cardiol (1999) 1.27
Temperature and ligand dependence of conformation and helical order in myosin filaments. Biochemistry (2003) 1.27
Association of elevation, urbanization and ambient temperature with obesity prevalence in the United States. Int J Obes (Lond) (2013) 1.24
Clinical and biochemical effects of dietary fish oil supplements in rheumatoid arthritis. J Rheumatol (1988) 1.24